Development of an Anthrax Vaccine

NIH RePORTER · NIH · N01 · $2,562,540 · view on reporter.nih.gov ↗

Abstract

This contract supports the advanced development of an immuno-enhanced version of the licensed anthrax vaccine through cGMP manufacturing and has an option for a Phase 1 clinical trial. The candidate vaccine will be formulated with an immunostimulant to minimize the amount of vaccine and time required to attain protective immunity.

Key facts

NIH application ID: 10434631
Project number: 272200800051C-P00009-9999-1
Recipient: EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR
Principal Investigator: SUKJOON PARK
Activity code: N01
Funding institute: NIH
Fiscal year: 2021
Award amount: $2,562,540
Award type: —
Project period: 2008-09-25 → 2021-07-07